when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Janssen Biotech Inc · catalysts · pharmadog

← back to Janssen Biotech Inc

Catalysts for Janssen Biotech Inc

140 tracked

LAZCLUZE (LAZERTINIB MESYLATE) — FDA approval

lazertinib mesylate

STELARA (USTEKINUMAB) — FDA approval

TREMFYA (GUSELKUMAB) — FDA approval

SIMPONI (GOLIMUMAB) — FDA approval

Janssen Biotech Inc

STELARA (USTEKINUMAB) — FDA approval

TREMFYA (GUSELKUMAB) — FDA approval

TREMFYA (GUSELKUMAB) — FDA approval

RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval

TALVEY (TALQUETAMAB-TGVS) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

STELARA (USTEKINUMAB) — FDA approval

BALVERSA (ERDAFITINIB) — FDA approval

RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval

TREMFYA (GUSELKUMAB) — FDA approval

RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval

LAZCLUZE (LAZERTINIB MESYLATE) — FDA approval

lazertinib mesylate

ERLEADA (APALUTAMIDE) — FDA approval

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

ERLEADA (APALUTAMIDE) — FDA approval

TALVEY (TALQUETAMAB-TGVS) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

STELARA (USTEKINUMAB) — FDA approval

RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval

TALVEY (TALQUETAMAB-TGVS) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

BALVERSA (ERDAFITINIB) — FDA approval

BALVERSA (ERDAFITINIB) — FDA approval

BALVERSA (ERDAFITINIB) — FDA approval

← prevpage 2 of 5next →